4basebio (LON:4BB) Trading 4.8% Higher – What’s Next?

4basebio PLC (LON:4BB)’s share price shot up 4.8% during mid-day trading on Wednesday . The stock traded as high as GBX 550 and last traded at GBX 550. Approximately 311 shares were traded during trading, a decline of 80% from the average daily volume of 1,576 shares. The stock had previously closed at GBX 525.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada cut their price target on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of GBX 1,400.

4basebio Stock Up 4.8%

The company has a market cap of £85.17 million, a price-to-earnings ratio of -5.05 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The firm’s fifty day moving average price is GBX 506.80 and its 200-day moving average price is GBX 533.90.

4basebio (LON:4BB) last issued its quarterly earnings data on Wednesday, May 20th. The company reported GBX (1.09) EPS for the quarter. The company had revenue of GBX 169 million during the quarter. Sell-side analysts predict that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Buying and Selling at 4basebio

In other 4basebio news, insider Amy Walker acquired 1,863 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of GBX 509 per share, for a total transaction of £9,482.67. 12.08% of the stock is owned by company insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.